Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 6 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
siG12D‐LODER in addition to standard chemotherapy for locally advanced pancreatic cancer	Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , siG12D-LODER	Pancreatic cancer	Gastrointestinal Cancer	2018	View \| Download
Pembrolizumab (KEYTRUDA) in combination with carboplatin-paclitaxel/Nab-paclitaxel for metastatic squamous non small cell lung cancer, first line	Carboplatin (Paraplatin) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , Paclitaxel (Taxol; paclitaxel albumin) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
PEGPH20 in addition to Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Ductal Adenocarcinoma	Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , Pegvorhyaluronidase alfa (PEGPH20)	Pancreatic cancer	Gastrointestinal Cancer	2018	View \| Download
Nab-paclitaxel in Combination with Gemcitabine for Resected Pancreatic Ductal Adenocarcinoma - Adjuvant Therapy	Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007)	Pancreatic cancer	Gastrointestinal Cancer	2017	View \| Download
Atezolizumab in combination with Nab-paclitaxel for unresectable, locally advanced or metastatic triple-negative breast cancer – first line	Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007)	Breast cancer	Breast Cancer	2018	View \| Download
Atezolizumab in combination with nab-paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer	Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007)	Breast cancer	Breast Cancer	2018	View \| Download

About

Devices, Diagnostics & Digital

About

Data Science & AI

Devices, Diagnostics & Digital

Insights (Public/Patient)

Medicines

Medicine Industry's Gateway to NICE

Support for Industry

Outputs & Publications